MarketCap
Facebook
X
Telegram
Interpace Biosciences Retained Earnings | IDXG
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Interpace Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -211 M | -235 M | -242 M | -249 M | -227 M | -212 M | -168 M | -141 M | -132 M | -120 M | -111 M | -99.9 M | -83.8 M | -79.3 M | -53.7 M | -41.8 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -41.8 M | -249 M | -150 M |
Quarterly Retained Earnings Interpace Biosciences
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -211 M | -210 M | -235 M | -233 M | -234 M | -234 M | -235 M | -244 M | -246 M | -248 M | -248 M | -249 M | -248 M | -249 M | -249 M | -247 M | -233 M | -229 M | -227 M | -223 M | -220 M | -216 M | -212 M | -212 M | -212 M | -212 M | -186 M | -186 M | -186 M | -186 M | -159 M | -141 M | -141 M | -141 M | -132 M | -132 M | -132 M | -132 M | -120 M | -120 M | -120 M | -120 M | -111 M | -111 M | -111 M | -111 M | -99.9 M | -99.9 M | -99.9 M | -99.9 M | -83.8 M | -83.8 M | -83.8 M | -83.8 M | -79.3 M | -79.3 M | -79.3 M | -79.3 M | -53.7 M | -53.7 M | -53.7 M | -53.7 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -53.7 M | -249 M | -162 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 257.93 | 1.18 % | $ 28.6 B | USA |
 |
Danaher Corporation
DHR
|
46.9 B | $ 230.45 | 1.76 % | $ 164 B | USA |
 |
IDEXX Laboratories
IDXX
|
6.39 B | $ 676.3 | 0.83 % | $ 54.4 B | USA |
 |
Illumina
ILMN
|
-392 M | $ 213.05 | 2.43 % | $ 33 B | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 100.61 | -0.09 % | $ 6.79 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-719 M | - | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 653.24 | 2.88 % | $ 18.8 B | USA |
 |
Mettler-Toledo International
MTD
|
9.24 B | $ 1 722.36 | 2.64 % | $ 35.5 B |  Schweiz |
 |
Natera
NTRA
|
-2.78 B | $ 319.38 | -12.2 % | $ 43.7 B | USA |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 338.13 | 8.07 % | $ 16.8 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.75 B | $ 50.36 | -0.98 % | $ 10.9 B |  Niderland |
 |
RadNet
RDNT
|
-95.4 M | $ 75.83 | -2.79 % | $ 5.7 B | USA |
 |
Senseonics Holdings
SENS
|
-1.02 B | $ 8.58 | 7.38 % | $ 358 M | USA |
 |
T2 Biosystems
TTOO
|
-584 M | - | -39.35 % | $ 313 K | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
-459 M | $ 2.17 | -10.91 % | $ 143 M | USA |
 |
Thermo Fisher Scientific
TMO
|
59.2 B | $ 694.85 | 2.62 % | $ 262 B | USA |
 |
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Trinity Biotech plc
TRIB
|
-79.1 M | $ 6.07 | 2.97 % | $ 2.18 B |  Irlanda |
 |
Brainsway Ltd.
BWAY
|
-98.4 M | $ 11.12 | 4.81 % | $ 378 M |  Israel |
 |
VolitionRx Limited
VNRX
|
-253 M | $ 0.2 | 3.39 % | $ 25.2 M |  Singapore |
 |
Waters Corporation
WAT
|
10.4 B | $ 458.04 | 1.06 % | $ 27.3 B | USA |
 |
Exagen
XGN
|
-314 M | $ 5.79 | -23.82 % | $ 125 M | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 151.28 | -1.4 % | $ 19 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 366.98 | 1.02 % | $ 30.5 B | USA |
 |
IQVIA Holdings
IQV
|
7.42 B | $ 271.72 | 2.59 % | $ 46.7 B | USA |
 |
Quotient Limited
QTNT
|
-725 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
75.7 M | - | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
168 M | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
-212 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
-18.6 M | - | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
223 M | - | - | $ 1.49 B | USA |
 |
Celcuity
CELC
|
-449 M | $ 66.73 | 3.9 % | $ 3.12 B | USA |
 |
DexCom
DXCM
|
2.43 B | $ 79.42 | -5.97 % | $ 31 B | USA |
 |
Agilent Technologies
A
|
1.39 B | $ 175.14 | 1.97 % | $ 49.7 B | USA |
 |
Castle Biosciences
CSTL
|
-224 M | $ 32.49 | -4.99 % | $ 942 M | USA |
 |
Anixa Biosciences
ANIX
|
-252 M | $ 3.16 | 4.29 % | $ 103 K | USA |
|
Biodesix
BDSX
|
-498 M | $ 8.51 | -57.13 % | $ 64.3 M | USA |
 |
BioNano Genomics
BNGO
|
-720 M | $ 1.15 | 4.54 % | $ 6.26 M | USA |
 |
Bioventus
BVS
|
-335 M | $ 10.61 | -0.66 % | $ 707 M | USA |
 |
Fulgent Genetics
FLGT
|
530 M | $ 23.68 | 26.9 % | $ 729 M | USA |
 |
CareDx, Inc
CDNA
|
-735 M | $ 78.47 | 2.8 % | $ 4.18 B | USA |